Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2010. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
| Metric | Value |
|---|---|
| Issued Share Capital (as of 31 July 2010) | 5,666,863,758 Ordinary shares of 25p each |
| Treasury Shares | 474,194,158 |
| Total Voting Rights | 5,192,669,600 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. It presents a static snapshot of share capital as of 31 July 2010.
Guidance, Outlook, and Risks
The filing text does not provide clear values for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under the Financial Services Authority's rules.
Important Facts for Investors to Verify
- The total number of voting rights is 5,192,669,600, which serves as the denominator for determining notification requirements under Disclosure and Transparency Rules.
- Approximately 474 million shares are held in Treasury and do not carry voting rights.
- The issued share capital consists of Ordinary shares with a nominal value of 25p each.